Optimization of protein therapeutics by directed evolution.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Drug Discovery Today

• Publication date

  2003-01-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1359-6446(02)02590-4PMID 12568781
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-α Fusion Protein in Cynomolgus Monkeys

  2002cited by this paper
• Enhancing the Anticoagulant Potency of Soluble Tissue Factor Mutants by Increasing their Affinity to Factor VIIa

  2002cited by this paper
• Tech.Sight. Phage display. Affinity selection from biological libraries.

  2002cited by this paper
• Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly.

  2002cited by this paper
• Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase.

  2002cited by this paper
• Wild-Type and A328W Mutant Human Butyrylcholinesterase Tetramers Expressed in Chinese Hamster Ovary Cells Have a 16-Hour Half-Life in the Circulation and Protect Mice from Cocaine Toxicity

  2002cited by this paper
• Expression of beta-galactosidase by recombinant respiratory syncytial viruses for microneutralization assay.

  2002cited by this paper
• Rational cytokine design for increased lifetime and enhanced potency using pH-activated “histidine switching”

  2002cited by this paper
• Affinity Selection from Biological Libraries

  2002cited by this paper
• Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation.

  2001cited by this paper
• Development and characterization of novel erythropoiesis stimulating protein (NESP)

  2001cited by this paper
• Directed evolution of proteins by exon shuffling

  2001cited by this paper
• In Vitro Affinity Maturation of Human IgM Antibodies Reactive with Tumor-Associated Antigens

  2001cited by this paper
• How enzymes adapt: lessons from directed evolution

  2001cited by this paper
• Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.

  2000cited by this paper
• Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides.

  2000cited by this paper
• In vitro selection and evolution of proteins.

  2000cited by this paper
• Increased Endosomal Sorting of Ligand to Recycling Enhances Potency of an Interleukin-2 Analog*

  2000cited by this paper
• Generation of Monoclonal Antibodies to Cryptic Collagen Sites by Using Subtractive Immunization

  2000cited by this paper
• Rational design of faster associating and tighter binding protein complexes

  2000cited by this paper
• Antibody engineering.

  2000cited by this paper
• Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity.

  2000cited by this paper
• Safety Assessment of Biotechnology-Derived Pharmaceuticals: ICH and Beyond

  1999cited by this paper
• A fully human antibody neutralising biologically active human TGFbeta2 for use in therapy.

  1999cited by this paper
• Directed Evolution of an Esterase from Pseudomonas fluorescens. Random Mutagenesis by Error-Prone PCR or a Mutator Strain and Identification of Mutants Showing Enhanced Enantioselectivity by a Resorufin-Based Fluorescence Assay

  1999cited by this paper
• Growth hormone binding affinity for its receptor surpasses the requirements for cellular activity.

  1999cited by this paper
• Evolution of a cytokine using DNA family shuffling

  1999cited by this paper
• Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.

  1999cited by this paper
• An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient.

  1999cited by this paper
• Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.

  1999cited by this paper
• Selection of Heregulin Variants Having Higher Affinity for the ErbB3 Receptor by Monovalent Phage Display*

  1998cited by this paper
• Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.

  1998cited by this paper
• Stepwise in vitro affinity maturation of Vitaxin, an αvβ3-specific humanized mAb

  1998cited by this paper
• Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.

  1997cited by this paper
• Cocaine detoxification by human plasma butyrylcholinesterase.

  1997cited by this paper
• Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice

  1997cited by this paper
• Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

  1997cited by this paper
• Degradative covalent reactions important to protein stability.

  1997cited by this paper
• Degradative covalent reactions important to protein stability

  1997cited by this paper
• Binding in the growth hormone receptor complex.

  1996cited by this paper
• Rapid, electrostatically assisted association of proteins

  1996cited by this paper
• Engineering epidermal growth factor for enhanced mitogenic potency

  1996cited by this paper
• The Biologic Activity and Molecular Characterization of a Novel Synthetic Interferon-Alpha Species, Consensus Interferon

  1996cited by this paper
• Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist.

  1995cited by this paper
• Rational Design of a Mouse Granulocyte Macrophage- Colony-stimulating Factor Receptor Antagonist (*)

  1995cited by this paper
• Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis.

  1995cited by this paper
• Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons.

  1995cited by this paper
• Safety evaluation of biological and biotechnology-derived medicines.

  1995cited by this paper
• Clinical issues in antibody design.

  1995cited by this paper
• Requirement of vascular integrin alpha v beta 3 for angiogenesis.

  1994cited by this paper
• In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity.

  1994cited by this paper
• Isolation of high affinity human antibodies directly from large synthetic repertoires.

  1994cited by this paper
• Increased antibody affinity and specificity by codon-based mutagenesis.

  1993cited by this paper
• Chimeric and humanized antibodies with specificity for the CD33 antigen.

  1992cited by this paper
• Antibody framework residues affecting the conformation of the hypervariable loops.

  1992cited by this paper
• Antibody engineering by codon-based mutagenesis in a filamentous phage vector system.

  1992cited by this paper
• Making antibody fragments using phage display libraries

  1991cited by this paper
• In vivo mutagenesis.

  1991cited by this paper
• Additivity of mutational effects in proteins.

  1990cited by this paper
• Reshaping human antibodies for therapy

  1988cited by this paper
• Replacing the complementarity-determining regions in a human antibody with those from a mouse

  1986cited by this paper

• Advancing Protein Therapeutics: Innovations In Rational Drug Design: A Review

  2025cites this paper
• In-Depth Review of Advanced Techniques in Protein Engineering in Therapeutic Innovations

  2025cites this paper
• Role of Mirikizumab in the Treatment of Inflammatory Bowel Disease—From Bench to Bedside

  2025influential citation
• The artificial amino acid change in the sialic acid-binding domain of the hemagglutinin neuraminidase of newcastle disease virus increases its specificity to HCT 116 colorectal cancer cells and tumor suppression effect

  2024cites this paper
• Preliminary Investigation and Therapeutic Efficacy Determination of a Novel Anti-IL-17A Antibody, Indikizumab

  2024cites this paper
• Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23

  2023cites this paper
• The Expanding Role of Chemistry in Optimizing Proteins for Human Health Applications.

  2021cites this paper
• The advent of de novo proteins for cancer immunotherapy.

  2020cites this paper
• Enzyme Engineering

  2019cites this paper
• Inhibition of PD1:PD-L1 interaction by an E. coli-derived optimized PD1 variant.

  2018cites this paper
• Improving the immunogenicity and protective efficacy of the EtMIC2 protein against Eimeria tenella infection through random mutagenesis.

  2018cites this paper
• Biophysical and Sequence-Based Methods for Identifying Monovalent and Bivalent Antibodies with High Colloidal Stability.

  2018cites this paper
• Selection Finder (SelFi): A computational metabolic engineering tool to enable directed evolution of enzymes

  2017cites this paper
• Data driven flexible backbone protein design

  2017cites this paper
• Engineering Therapeutic Enzymes

  2017cites this paper
• Industrial Production of Therapeutic Proteins: Cell Lines, Cell Culture, and Purification

  2017cites this paper
• Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A

  2016cites this paper
• Discovery of binding proteins for a protein target using protein–protein docking‐based virtual screening

  2014cites this paper
• Somatic hypermutation maintains antibody thermodynamic stability during affinity maturation

  2013cites this paper
• A population-based experimental model for protein evolution: effects of mutation rate and selection stringency on evolutionary outcomes.

  2013cites this paper
• Directed evolution of bacteriorhodopsin for applications in bioelectronics

  2013cites this paper
• Engineering the Repeats-in-Toxin Domain for Biotechnology Applications

  2012cites this paper
• Metabolic engineering of recombinant protein secretion by Saccharomyces cerevisiae.

  2012cites this paper
• Industrial Production of Therapeutic Proteins: Cell Lines, Cell Culture, and Purification

  2012cites this paper
• Discovery of improved EGF agonists using a novel in vitro screening platform.

  2011cites this paper
• Matériaux biologiques et composés, et utilisations correspondantes

  2010cites this paper
• Combinatorial engineering of adeno associated virus vectors

  2009cites this paper
• Effect of highly fluorinated amino acids on protein stability at a solvent-exposed position on an internal strand of protein G B1 domain.

  2009cites this paper
• Protein pharmaceuticals: discovery and preclinical development.

  2009cites this paper
• Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine.

  2009cites this paper
• ANTIBODY PURIFICATION: DRIVERS OF CHANGE

  2008cites this paper
• Conception de Ligands Protéiques par Bioinformatique et Modélisation Moléculaire

  2007cites this paper
• Drug Discovery and Delivery in the 21st Century

  2006cites this paper
• Electrophoresis of pharmaceutical proteins: Status quo

  2006cites this paper
• Improving random mutagenesis by purification of the oligonucleotide variants.

  2005cites this paper
• [Toward creation of proteins by combination of block shuffling and in vitro selection methods].

  2005cites this paper
• Integrating cell-level kinetic modeling into the design of engineered protein therapeutics

  2005cites this paper
• Directed evolution in chemical engineering

  2005cites this paper
• Engineering highly active enzymes with altered substrate selectivities

  2005cites this paper
• Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast

  2005cites this paper
• Data management solutions for protein therapeutic research and development.

  2005cites this paper
• Creating the next generation of protein therapeutics through rational drug design.

  2005cites this paper
• Directed evolution of enzymes for product chemistry.

  2004cites this paper
• Neue Biopharmazeutika durch Manipulation pharmakologischer Parameter

  2004cites this paper
• Kinetic Exclusion Assay Technology: Characterization of Molecular Interactions

  2004cites this paper
• Heterotachy and Functional Shift in Protein Evolution

  2003cites this paper
• Medicines in the 21st century Or pills, politics, potions, and profits: Where is public policy?

  2003cites this paper
• Expanding the clinical utility of therapeutic proteins: activated protein C variants with improved pharmacological properties.

  2003cites this paper
• Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A

  year unknowncites this paper